# US 2014/0155344 A1 · Combination therapy methods for treating proliferative diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155344 A1 - Document ID: US20140155344A1 - Status: Published application - Kind: A1 - Application number: 13/701,001 - Filed: 2011-05-20 - Published: 2014-06-05 - Earliest claimed: 2010-06-07 - Inventors: Neil P. Desai; Patrick Soon-Shiong - Web page: https://patentgrep.com/patent/US20140155344A1 ## CPC - A61K 31/337: having four-membered rings, e.g. taxol - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/146: {with organic macromolecular compounds} - A61K 9/5169: {Proteins, e.g. albumin, gelatin} - A61K 31/16: Amides, e.g. hydroxamic acids - A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol - A61K 31/282: Platinum compounds - A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom - A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 11/00: Drugs for disorders of the respiratory system - A61P 13/10: of the bladder - A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives - A61P 17/00: Drugs for dermatological disorders - A61P 35/00: Antineoplastic agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that modifies the epigenetics in a cell. ## Claims ### Claim 1 A method of treating a proliferative disease in an individual comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising a taxane and a carrier protein, and b) an effective amount of at least one other agent that modifies the epigenetics in a cell. ### Claim 2 (depends on 1) The method according to claim 1, wherein said other agent is an inhibitor of histone deacetylase. ### Claim 3 (depends on 2) The method according to claim 2, wherein said other agent is vorinostat. ### Claim 4 (depends on 3) The method according to claim 3, further comprising administering to said individual a platinum-based agent. ### Claim 5 (depends on 1) The method according to claim 1, wherein said other agent is an inhibitor of DNA methylransferase. ### Claim 6 (depends on 5) The method according to claim 5, wherein the other agent is azacitidine. ### Claim 7 (depends on 5) The method according to claim 5, wherein the other agent is decitabine. ### Claim 8 (depends on 1) The method according to claim 1, wherein the proliferative disease is cancer. ### Claim 9 (depends on 8) The method according to claim 8, wherein the cancer is breast cancer. ### Claim 10 (depends on 9) The method according to claim 9, wherein the individual is negative for ER, PR, or HER2. ### Claim 11 (depends on 10) The method according to claim 10, wherein the individual is negative for ER, PR, and HER2. ### Claim 12 (depends on 8) The method according to claim 8, wherein the cancer is ovarian cancer. ### Claim 13 (depends on 8) The method according to claim 8, wherein the cancer is non-small lung cancer. ### Claim 14 (depends on 1) The method according to claim 1, wherein the composition comprising nanoparticles comprising taxane and albumin and the other agent are administered simultaneously. ### Claim 15 (depends on 1) The method according to claim 1, wherein the composition comprising nanoparticles of taxane and albumin and the other agent are administered sequentially. ### Claim 16 (depends on 1) The method according to claim 1, wherein the composition comprising nanoparticles of taxane and albumin and the other agent are administered concurrently. ### Claim 17 (depends on 1) The method according to claim 1, wherein the taxane is paclitaxel. ### Claim 18 (depends on 1) The method according to claim 1, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm. ### Claim 19 (depends on 1) The method according to claim 1, wherein the carrier protein is albumin. ### Claim 20 (depends on 19) The method according to claim 19, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is less than about 1:1 to about 18:1. ### Claim 21 (depends on 20) The method according to claim 20, wherein the weight ratio of the albumin and the taxane in the nanoparticle composition is less than about 1:1 to about 9:1. ### Claim 22 (depends on 1) The method according to claim 1, wherein the individual is a human. ### Claim 23 A kit comprising: a) a composition comprising nanoparticles comprising a taxane and a carrier protein, and b) an effective amount of at least one other agent that modifies the epigenetics in a cell. ### Claim 24 (canceled)